{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T11:17:48Z","timestamp":1761823068294,"version":"3.40.4"},"reference-count":14,"publisher":"S. Karger AG","issue":"2-3","license":[{"start":{"date-parts":[[2006,11,15]],"date-time":"2006-11-15T00:00:00Z","timestamp":1163548800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2006,11,15]],"date-time":"2006-11-15T00:00:00Z","timestamp":1163548800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cerebrovasc Dis"],"published-print":{"date-parts":[[2007]]},"abstract":"<i>Background:<\/i> With the recent increase in the use of antithrombotic therapy, intracerebral hemorrhage (ICH) has been found to be a common complication. We determined whether the use of oral antithrombotic therapy and the patients\u2019 preexisting comorbidities were predictive of cerebellar hemorrhage (CH; previously reported to be associated with anticoagulants) as compared to other ICH, and whether antithrombotic therapy affected the clinical severity of CH. <i>Methods:<\/i> A study of 327 consecutive patients hospitalized in our institute within 3 days after the onset of ICH, including 38 patients with a CH. <i>Results:<\/i> CH accounted for 12% of all ICH, 75% of which occurred in patients on warfarin therapy with an international normalized ratio (INR) for prothrombin time >2.5 (p < 0.0001), and 33% of which occurred in patients on ticlopidine therapy (p = 0.017). Warfarin therapy with an INR >2.5 and high blood glucose on admission were independently predictive of CH as compared to other ICH. In addition, previous ischemic stroke (p = 0.002) and heart diseases (p = 0.018) were more prevalent in patients with CH than in those with other ICH. The number of major arteriosclerotic comorbidities and risk factors was also independently predictive of CH risk. <i>Conclusions:<\/i> We confirmed that warfarin therapy with an INR >2.5 is associated with CH. Patients with CH frequently had arteriosclerotic comorbidities requiring antithrombotic therapy that can complicate their acute management.<\/jats:p>","DOI":"10.1159\/000097046","type":"journal-article","created":{"date-parts":[[2008,5,30]],"date-time":"2008-05-30T07:28:44Z","timestamp":1212132524000},"page":"109-116","source":"Crossref","is-referenced-by-count":15,"title":["Antithrombotic Therapy and Predilection for Cerebellar Hemorrhage"],"prefix":"10.1159","volume":"23","author":[{"given":"Kazunori","family":"Toyoda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Okada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Setsuro","family":"Ibayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tooru","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kotaro","family":"Yasumori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Fukui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Uwatoko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriko","family":"Makihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuo","family":"Minematsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2006,11,15]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1136%2Fbmj.324.7336.S71"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1159%2F000090356"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002%2Fana.410160505"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1001%2Farchinte.164.8.880"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1161%2F01.STR.0000174189.81153.85"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1001%2Fjama.280.22.1930"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1212%2F01.wnl.0000179178.37713.69"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007%2Fs00415-005-0659-5"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1161%2F01.STR.0000196991.03618.31"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1161%2F01.STR.27.8.1304"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1161%2F01.STR.0000124459.33597.00"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016%2F0002-9343%2892%2990268-G"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016%2Fj.thromres.2004.09.002"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056%2FNEJMoa042991"}],"container-title":["Cerebrovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/97046","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/97046","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T02:59:23Z","timestamp":1745463563000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000097046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11,15]]},"references-count":14,"journal-issue":{"issue":"2-3","published-online":{"date-parts":[[2007,2,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000097046","archive":["Portico"],"relation":{},"ISSN":["1015-9770","1421-9786"],"issn-type":[{"type":"print","value":"1015-9770"},{"type":"electronic","value":"1421-9786"}],"subject":[],"published":{"date-parts":[[2006,11,15]]}}}